Return to content in this issue


Dupilumab: A Review of Present Indications and Off-Label Uses

Muñoz-Bellido FJ1,2,3, Moreno E1,2,3,4, Dávila I1,2,3,4

1Allergy Service, Hospital Universitario de Salamanca, Spain
2Instituto Biosanitario de Salamanca, Salamanca, Spain
3Department of Biomedical and Diagnostic Sciences, University of Salamanca, Salamanca, Spain

J Investig Allergol Clin Immunol 2022; Vol 32(2) : 97-115
doi: 10.18176/jiaci.0682

Recent advances in our understanding of T2 inflammation have revealed more diseases in which T2 inflammation is involved. Dupilumab is a recently developed monoclonal antibody that blocks signaling of IL-4 and IL-13, both of which are crucial cytokines in the T2 response. New possible indications are increasingly explored and include skin diseases, such as prurigo nodularis, nummular eczema, allergic contact dermatitis, chronic hand eczema, spontaneous chronic urticaria, bullous pemphigoid, alopecia areata, and Netherton syndrome, as well as respiratory diseases, such as allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, and allergic rhinitis. In addition, eosinophilic gastrointestinal disorders, particularly eosinophilic esophagitis, and food allergy, are also research fields of interest. Here, we review published data and clinical trials examining the use of dupilumab in these disorders.

Key words: Dupilumab, Alopecia areata, Allergic bronchopulmonary aspergillosis, Allergic contact dermatitis, Chronic urticaria, Eosinophilic esophagitis, Cutaneous autoimmune bullous diseases, Food allergy